

# 3CTN Annual Stakeholder Meeting & Workshops 2023

## Canadian Cancer Clinical Trials Network WORKSHOPS

October 26, 2023; 9:00 am – 4:30 pm ET  
Holiday Inn Toronto Downtown Centre, Wellesley Room

### Workshop #1: Implementing Decentralized Clinical Trials

*Identifying practical solutions to overcome implementation barriers.*

9 am – 12:15 pm





**Session Facilitators:** **Stephen Sundquist**, *Executive Director, 3CTN*; **Kathy Brodeur-Robb**, *Executive Director, C17*

**Summary:** Decentralized Clinical Trials (DCTs) help enable clinical trial participation by creating pathways of access between sites offering a clinical trial and patients at non-participating sites. This session will provide an update on the ongoing work to implement DCT elements internationally and within Canada, as well as an update on the current DCT landscape. Workshop participants will contribute to facilitated discussions to develop actionable approaches to overcome anticipated barriers or challenges to implementation.

**Link to Q&A:** <https://app.sli.do/event/7raesbKXYPwXyuV6SXqLr1> (event code: 3CTNASM)  
*Questions can be submitted in advance and in real-time throughout the session.*

Time	Topic
8:30 am	<b>Breakfast</b>
9:00 am	<b>Introduction &amp; Workshop Objectives</b> <ul style="list-style-type: none"><li>• <b>Stephen Sundquist</b>, <i>Executive Director, 3CTN</i></li></ul>
9:15 am	<b>Australian Teletrials Program</b> <i>Learn about the Australian Teletrials Program and the adoption at Western New South Wales Local Health District</i> <ul style="list-style-type: none"><li>• <b>Sabe Sabesan</b> , <i>Medical Oncologist, Director, Medical Oncology, Townsville Cancer Centre, Townsville Hospital</i></li><li>• <b>Rob Zielinski</b> , <i>Medical Oncologist, Director, Clinical Trials Unit, Central West Cancer Centre, Orange Base Hospital, Western NSW Local Health District</i></li></ul>
9:50 am	<b>CRAFT Proof of Concept Summary</b> <ul style="list-style-type: none"><li>• <b>Diana Kato</b>, <i>Manager, Operations, 3CTN</i></li></ul>
10:05 am	<b>Implementation of DCT Models</b> <i>Lightning Round: Updates of DCT implementation across Canada</i> <ul style="list-style-type: none"><li>• <b>Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I</b> <b>Alecia Lim</b>, <i>Clinical Trial Unit Manager, BC Children's Hospital</i> <b>Hina Johnstone</b> , <i>Developmental Therapeutics (DVL) Team Lead, BC Children's Hospital</i></li><li>• <b>A phase 2 study of mirdametinib and vinblastine for newly diagnosed or previously untreated patients with pediatric low-grade glioma and activation of the MAPK pathway</b> <b>Linda Hershon</b>, <i>Clinical Research Nurse, CHU Sainte-Justine</i></li></ul>

Time	Topic
10:20 am	<p><b>(CCTG) SC.28 / SEAMLESS: A Pragmatic Multi-Site Randomized Waitlist-Controlled Trial of a Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors</b></p> <ul style="list-style-type: none"> <li>• <b>Harriet Richardson</b> , Senior Investigator - Canadian Cancer Trials Group &amp; Cancer Care and Epidemiology</li> </ul>
10:35 am	<b>Networking Break</b>
10:55 am	<p><b>CCTG Patient Sharing Scenarios: Decision Making Tool</b></p> <ul style="list-style-type: none"> <li>• <b>Patti O'Brien</b> , Innovation Lead/Study Coordinator, Canadian Cancer Trials Group</li> </ul>
11:05 am	<p><b>DCT Landscape Updates</b> Updates on the DCT landscape</p> <ul style="list-style-type: none"> <li>• <b>Stephen Sundquist</b>, Executive Director, 3CTN</li> </ul>
11:10 am	<p><b>Concurrent Breakout Sessions</b> Using a trial example, identify components of the study protocol that can be implemented remotely (conduct a SWOT analysis if needed). List the actionable next steps for site implementation. For any challenges identified, describe what needs to be addressed.</p>
11:40 am	<p><b>Report Out &amp; Open Discussion</b> Report out from the breakout sessions, with a focus on discussing opportunities, overcoming barriers, actionable next steps and calls to action. Attendees are invited to bring forward DCT implementation questions from their own trial case examples for discussion.</p>
12:10 pm	<p><b>Next Steps &amp; Closing Remarks</b> Stephen Sundquist</p>
12:15 pm	<b>Networking Lunch</b>

# 3CTN Annual Stakeholder Meeting & Workshops 2023

## Workshop #2: Equity, Diversity and Inclusion (EDI) in Cancer Clinical Trials

*Improving access to and awareness of clinical trials for underrepresented communities*

1:00 – 4:30 pm



**Session Facilitators:** **Raisa Chowdhury**, *Project Coordinator, 3CTN*; **Michelle Audoin**, *Patient Advocate, OICR*

**Summary:** The workshop aims to address the need to enhance access and participation of underrepresented communities in cancer clinical trials. This session will provide an overview of the barriers and opportunities of EDI in trials and provide an update on the 3CTN EDI Framework and Toolkit. Stakeholders will provide updates and progress on EDI efforts within their respective institutions. Workshop participants will contribute to facilitated discussions, share ideas and identify practical next steps to enhance EDI within their local institutions.

**Link to Q&A:** <https://app.sli.do/event/7raesbKXYPwXyuV6SXqLr1> (event code: 3CTNASM)  
*Questions can be submitted in advance and in real-time throughout the session.*

Time	Topic
1:00 pm	<b>Introduction &amp; Workshop Objectives</b> <ul style="list-style-type: none"> <li><b>Raisa Chowdhury</b>, <i>Project Coordinator</i></li> </ul>
<b>Understanding Perspective from Underrepresented Populations</b>	
1:10 pm	<b>The WHY: Importance of EDI</b> <ul style="list-style-type: none"> <li><b>Michelle Audoin</b>, <i>Patient Advocate</i></li> </ul>
1:25 pm	<b>Importance of Indigenous Cultural Safety (ICS)</b> <ul style="list-style-type: none"> <li><b>Laura McNab-Coombs</b>, <i>Indigenous Health Research Facilitator, BC NEIHR</i></li> </ul>
<b>Applying EDI Principles and Practices in Clinical Trials</b> <i>Learn more about how others are improving EDI in clinical trials</i>	
1:35 pm	<b>EDI in Clinical Trials: Barriers and Opportunities</b> <ul style="list-style-type: none"> <li><b>Raisa Chowdhury</b>, <i>Project Coordinator, 3CTN</i></li> </ul>
1:55 pm	<b>Improving Trial Design</b> <ul style="list-style-type: none"> <li><b>Anna Johnson</b>, <i>EDIIA Lead, Canadian Cancer Trials Group</i></li> </ul>
2:15 pm	<b>Collection of Race and Ethnicity Data</b> <ul style="list-style-type: none"> <li><b>Stacey Marjerrison</b> , <i>Pediatric Hematologist/Oncologist, McMaster Children's Hospital</i></li> </ul>
2:35 pm	<b>Setting Adolescent and Young Adult (AYA) Cancer Priorities in Clinical Trials</b> <ul style="list-style-type: none"> <li><b>Chantale Thurston</b>, <i>Patient Advocate, Board Member, AYA Can</i></li> </ul>
2:40 pm	<b>Networking Break</b>
3:00 pm	<b>Developing 3CTN's EDI Framework</b> <ul style="list-style-type: none"> <li><b>Raisa Chowdhury</b>, <i>Project Coordinator, 3CTN</i></li> </ul>
3:10 pm	<b>Breakout Sessions</b> <i>Participate in a facilitated discussions to identify opportunities to improve EDI locally, strategies to overcome identified challenges and develop actionable next steps.</i>

Time	Topic
3:55 pm	<b>Report Out</b> <i>Report out from the breakout sessions, with a focus on actionable next steps and calls to action</i>
4:25 pm	<b>Next Steps &amp; Closing Remarks</b> <ul style="list-style-type: none"><li>• <b>Stephen Sundquist</b>, <i>Executive Director, 3CTN</i></li></ul>
4:30 pm	<b>Networking</b>

## Sponsors

Gold Sponsor



Sponsor



# 3CTN Annual Stakeholder Meeting & Workshops 2023

## Meet Our Speakers:

### **Decentralized Clinical Trial (DCT) Workshop**

**Stephen Sundquist**, *Executive Director, Canadian Cancer Clinical Trial Network (3CTN)*

Stephen has over 25 years of experience in clinical trials and health programs' leadership. His clinical research expertise includes roles in pharma, CRO and academic settings involving the conduct of Phase 1-3b drug, biologic, and device trials across a wide range of therapeutic areas. In his role as Executive Director for the Canadian Cancer Clinical Trials Network (3CTN), Stephen is responsible for leading initiatives designed to improve equitable trial access, patient accrual as well as the efficient, high-quality conduct of academic cancer clinical trials led by the nearly 60 Network Cancer Centres across Canada.

**Kathy Brodeur-Robb**, *Executive Director, C17*

Kathy is an Executive Director with over 18 years' experience with C17 Council, a national non-profit research network linking all pediatric oncology/ hematology/ BMT programs across Canada. She is knowledgeable and involved in the current regulatory, ethics, legal and political landscape of clinical research in Canada and a contributing member of numerous national committees.

**Sabe Sabesan**, *Medical Oncologist, Director, Medical Oncology, Townsville Cancer Centre, Townsville Hospital*

Professor Sabesan BMBS PhD FRACP is a senior Medical Oncologist at the Townsville Cancer Centre and the Clinical Director of the Australian Teletrial Program, Office of Research and Innovation, Queensland Health. He led the development of various teleoncology models including the Queensland Remote Chemotherapy supervision model and the Australasian Teletrial model to improve access to high quality care closer to home for RRR communities. Currently as the president-Elect of the Clinical Oncology Society of Australia, he plans to advocate for creating equitable health system in Australia and healthier workplace culture as the foundation for workforce wellbeing.

**Robert Zielinski**, *Medical Oncologist, Director, Clinical Trials Unit, Central West Cancer Centre, Orange Base Hospital, Western NSW Local Health District*

Rob is a senior staff specialist in medical oncology currently practicing in regional NSW at the Central West Cancer Care Centre, Orange NSW. He is an Associate Professor with the Faculty of Medicine, Western Sydney University. He is also the current Director of the Orange Hospital Clinical Trials Unit and clinical lead for the Rural, Regional & Remote Clinical Trial Enabling Program. He moved from Sydney to Orange in 2013 after completing his oncology training and a genitourinary fellowship at the British Columbia Cancer Agency in Vancouver.

Rob's passion is improving the disparity in cancer outcomes between rural and metropolitan patients and has a particular passion for increasing access to clinical trials to rural patients.

Research interests include implementation science, improving the patient experience and direct clinical research through involvement in investigator and sponsor led clinical trials. He also assists the Royal Australasian College of Physicians in preparation of basic physician training.

**Diana Kato**, *Manager, Operations, 3CTN*

Diana is a Project Management Professional with over 10 years' experience in research administration and project management for non-for-profit organizations. In her current role, she is responsible for the day-to-day operations of the Canadian Cancer Clinical Trials Network (3CTN). In addition, she works with stakeholders across 50 cancer centres to lead and implement strategic projects to improve the academic cancer clinical trials environment.

**Alecia Lim, Clinical Trial Unit Manager, BC Children's Hospital**

Alecia, CCRP, is currently the Clinical Trials Unit Manager, overseeing the Operational team on coordination of clinical trials upon activation as well as program development. She brings with her 12 years of experience in clinical research from early to late phase as well as bone marrow transplant coordination, with majority of her time at Oncology/Hematology/BMT at BC Children's Hospital. Her passion for management and cancer research, fuels her to continue striving to help advance treatment options and availability for patients at BC Children's Hospital.

**Hina Johnstone, Developmental Therapeutics (DVL) Team Lead, BC Children's Hospital**

Hina has worked as a Pediatric Oncology Nurse for over 20 years, most recently in Phase I/II clinical trials, before moving to Vancouver in 2017. She currently works as a Clinical Research Coordinator and leads the *Developmental Therapeutics (DVL)* team at BC Children's Hospital CTU, overseeing the DVL portfolio, supporting the DVL CRAs and operational management of phase I/II studies. Using her nursing experience, she supports the clinical team with phase I/II study patients visits and AE/SAE documentation and reporting.

**Linda Hershon, Clinical Research Nurse, CHU Sainte-Justine**

Linda Hershon is an experienced pediatric oncology clinical research nurse working at CHU Sainte Justine. She is the Children's Oncology Group lead Clinical Research Associate for her institution and enjoys mentoring team members. She is vice-president of the Quebec Association for Nurses in Oncology and medical director of the Tip of the Toes Foundation that brings teens and young adults living with cancer to wilderness expeditions.

**Harriet Richardson, Senior Investigator - Canadian Cancer Trials Group & Cancer Care and Epidemiology**

Dr. Richardson received her PhD in Epidemiology & Biostatistics from McGill University in 2003 where she studied the natural history of HPV and cervical neoplasia. She became a Senior Investigator at the Canadian Cancer Trials Group in 2004 and currently oversees the Breast Cancer Prevention portfolio and the Supportive Care Committee. Dr. Richardson is an Associate Professor in the Department of Public Health Sciences, at Queen's University where she teaches and is the current Graduate Coordinator. Her research interests include cancer prevention, cancer symptom management and the use of etiological and prognostic biomarkers in population-based studies.

**Patti O'Brien, Innovation Lead/Study Coordinator, Canadian Cancer Trials Group**

Patti O'Brien has her BSc in Occupational Therapy from Queen's University and MSc in Rehabilitation Sciences from UBC. After working as an Occupational Therapist for a decade, Patti began working at the Canadian Cancer Trials Group in 2005. Patti has worked at CCTG in the Office of Clinical Trials Management as a Study Coordinator and Team Leader. She is now currently the Innovation Lead working on a variety of cross-portfolio initiatives including patient-sharing initiatives including implementation of CRAFT and other similar scenarios.

---

**Equity Diversity and Inclusion (EDI) in Clinical Trials Workshop**

**Raisa Chowdhury, Project Coordinator, 3CTN**

# 3CTN Annual Stakeholder Meeting & Workshops 2023

Raisa is a Project Coordinator at the Canadian Cancer Clinical Trials Network (3CTN). She has worked with 3CTN for 2 years and in her current role she supports both the Trial Portfolio and Operations Team. She is responsible for the coordination of multiple strategic projects and activities such as 3CTN's Equity Diversity and Inclusion (EDI) initiative to help improve access to academic cancer clinical trials in Canada.

**Michelle Audoin**, *Patient Advocate, Ontario Institute Cancer Research (OICR) Patient Family Advocate Council*

Michelle lives with Stage 4 breast cancer and advocates for the unmet needs of under supported communities in the cancer care space, with a focus on health equity and the patient voice. She is involved in many cancer organizations and awareness campaigns and loves to speak to healthcare agencies and on panels about her own experiences navigating cancer as a Black woman. Michelle comes from an education background and is a mom.

**Laura McNab-Coombs**, *Indigenous Health Researcher Facilitator, BC NEIHR*

Laura McNab-Coombs is a Métis researcher and biomedical sciences student whose roots on her father's side run deep in Battleford Saskatchewan, while those of her mother are of settler ancestry (England). She is currently employed with the BC NEIHR as an Indigenous Health Research Facilitator for both the Interior and North, thus dividing her time between the unceded ancestral territories of the Sinixt and Lheidli T'enneh (Dakelh) peoples. Laura's research interests lie in combatting anti-Indigenous racism in the healthcare (amongst other) system, women's health and sports performance, and Indigenous health and wellbeing.

**Anna Johnson**, *Equity, Diversity, Inclusivity, Indigenization, and Accessibility (EDIIA) Lead, CCTG*

Anna joined CCTG in October 2022 as the Equity, Diversity, Inclusivity, Indigenization, and Accessibility (EDIIA) Lead. In this role, Anna works to implement the objectives and activities in CCTG's EDIIA Action Plan. She is currently finishing her PhD in Sociology through the University of Guelph. Prior to joining CCTG, Anna worked in Indigenous justice on Tyendinaga Mohawk Territory, in the Office of Indigenous Initiatives at the University of Guelph, and as a researcher for the Centre for the Study of Social and Legal Responses to Violence.

**Stacey Marjerrison**, *Pediatric Hematologist/Oncologist, McMaster Children's Hospital*

Dr. Stacey Marjerrison is a pediatric oncologist and the Medical Director of the Pediatric Oncology Late Effects Program at the McMaster Children's Hospital, as well as an Associate Professor of Pediatrics at McMaster University, with an Associate appointment to the Department of Health Research Methods, Evidence and Impact. She holds the Ronald Barr Professorship in Pediatric Oncology as the inaugural recipient. Dr. Marjerrison's areas of research interest are in supportive care for children with cancer, and in the interaction between socio-demographic determinants of health and malignancy. As applied to survivors of childhood cancer, this includes evaluating and building care programs that encourage survivors to engage in healthy active lifestyles. More broadly, this research interest focuses on provision of care for marginalized populations, including Indigenous children in Canada and for all children in low-income countries. Finally, Dr. Marjerrison is the lead of the Social justice, Indigenization and Inclusion working group of the newly formed Canadian Pediatric Cancer Consortium.

**Chantale Thurston, Board Member and AYA Patient Representative, AYA CAN - Canadian Cancer Advocacy**

Chantale was born and raised in Winnipeg and is an accountant during the day. During her free time, she is the board chair of AYA Can – Canadian Cancer Advocacy which is a peer-led national charity that advocates for adolescents and young adults (AYA) affected by cancer. She also sits on the Management Committee of 3CTN, the CAPO Advocacy Committee, the BiocanRX's Learning Institutes working group, is a co-lead for the AYA Partnership Setting Priority, and is a co-lead for one of the CPCC matrices. She is also involved with various CancerCare Manitoba patient advisor groups.

Chantale was diagnosed in 2017 with Stage IV Appendix Cancer after pursuing fertility to try to have a second child. She underwent 4 rounds of chemotherapy and then an intense HIPEC surgery and has been No Evidence of Disease (NED) since. Chantale is very busy in the evenings with her active 9-year-old, her husband and their dog Charlie.